A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration

This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.

本研究为一项III期多中心随机双盲阳性对照临床试验，旨在对比玻璃体内注射雷珠单抗（ranibizumab）与维替泊芬（Visudyne）光动力疗法（PDT）治疗黄斑中心凹下新生血管性黄斑变性的疗效。